Bacil Pharma Ratios

Bacil Pharma Ltd Ratios

The Bacil Pharma Ltd Ratios page provides a complete fundamental analysis of Bacil Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Bacil Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Bacil Pharma Ltd (NSE: , BSE: 524516) is currently trading at ₹48.10, with a market capitalization of ₹726.69M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Bacil Pharma Ltd remains a key stock for fundamental analysis using Bacil Pharma Ltd Ratios.

Bacil Pharma Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Bacil Pharma Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Bacil Pharma Ltd Ratios.

Historically, the Bacil Pharma Ltd P/E ratio has shown strong fluctuations:

The decline in Bacil Pharma Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Bacil Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

Bacil Pharma Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Bacil Pharma Ltd P/S ratio currently stands at 0, an important part of Bacil Pharma Ltd Ratios for revenue valuation.

Historical P/S ratio:

A stable or declining Bacil Pharma Ltd P/S ratio indicates cautious market sentiment.

Bacil Pharma Ltd Price to Cash Flow Ratio (P/CF)

The Bacil Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Bacil Pharma Ltd Price to Cash Flow Ratio:

The declining Bacil Pharma Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Bacil Pharma Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Bacil Pharma Ltd EV currently stands at ₹0, representing the total company valuation including debt.

Historical EV trend:

Bacil Pharma Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Bacil Pharma Ltd EV/EBITDA ratio is currently 0, a key metric in Bacil Pharma Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

Stable Bacil Pharma Ltd EV/EBITDA indicates balanced valuation.

Bacil Pharma Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Bacil Pharma Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

Bacil Pharma Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Bacil Pharma Ltd ROE currently stands at 0%, showing profitability and capital efficiency.

Historical ROE:

Declining ROE indicates pressure on profitability.

Bacil Pharma Ltd Ratios Analysis Summary

The Bacil Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Bacil Pharma Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Bacil Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.